Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based biopharmaceutical firm AbbVie has expanded its global operations for small molecule and biologics manufacturing by acquiring a small molecule active pharmaceutical ingredient (API) manufacturing site in Singapore's Tuas Biomedical Park.
Subscribe to our email newsletter
The new 120,000m² facility will provide increased capacity for compounds within the company’s immunology and oncology pipelines.
The Singapore site includes a contained API facility, additional buildings and ancillary equipment, with the API facility scheduled to be fully operational by 2016.
AbbVie Operations senior vice-president Azita Saleki-Gerhardt said: "The Singapore site will help to strengthen our global manufacturing capabilities, offering a higher degree of flexibility and scale.
"The facility will support new technologies and the growth of our pipeline in immunology and oncology, helping us to address significant unmet medical needs for patients around the world."
On this property, the company will also build a bulk biologics manufacturing facility, which is scheduled to be operational in 2019.
Singapore Economic Development Board executive director of Biomedical Sciences and Consumer Businesses Kevin Lai said: "Singapore offers a neutral and trusted location for pharmaceutical companies to orchestrate and expand their operations across the region.
"We continue to see strong growth in biopharmaceutical manufacturing as companies, such as AbbVie, choose Singapore to launch and manufacture their high value-added products for the region and beyond."
Currently, the company’s manufacturing network includes thirteen sites across the US, Europe, Asia and Puerto Rico, as well as strategic partnerships with third-party manufacturers.